Emerging Therapies in Relapsed or Refractory Multiple Myeloma

Kenneth Shain, MD, PhD reviews advances in treatment of relapsed and refractory multiple myeloma and data presented at 2021 International Myeloma Workshop.

EP. 1: Relapsed/Refractory Multiple Myeloma Landscape

November 12th 2021

Kenneth Shain, MD, PhD provides an overview of recent advances in the treatment of relapsed and refractory multiple myeloma.

EP. 2: Melphalan flufenamide

November 12th 2021

Multiple myeloma expert Dr Kenneth Shain discusses mechanism of action of melphalan flufenamide and the advantage it might offer to fight cancer cells.

EP. 3: OCEAN Trial

November 12th 2021

Kenneth Shain, MD, PhD reviews phase 3 OCEAN study design and safety and efficacy data from patients with RRMM treated with melphalan flufenamide + dexamethasone doublet or pomalidomide + dexamethasone.

EP. 4: PORT Trial

November 12th 2021

Multiple myeloma expert Dr Kenneth Shain discusses the PORT study comparing central vs peripheral administration of melphalan flufenamide.

EP. 5: Emerging Therapies in RRMM

November 12th 2021

Dr Kenneth Shain, a multiple myeloma expert, discusses emerging therapies with newer mechanisms of action for patients with RRMM.

EP. 6: Management of Patients with RRMM

November 12th 2021

Kenneth Shain, MD, PhD discusses multiple myeloma disease measurement, management, and personalization of treatment going forward.